

NOVO NORDISK A S  
Form 6-K  
December 20, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**December 17, 2012**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## **Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 17 December 2012** On 9 November 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.5 billion in the period from 9 November 2012 to 29 January 2013.

Since the announcement as of 10 December 2012, the following transactions have been made under the programme:

|                                        | <b>Number of shares</b> | <b>Average purchase price</b> | <b>Transaction value, DKK</b> |
|----------------------------------------|-------------------------|-------------------------------|-------------------------------|
| <b>Accumulated, last announcement</b>  | <b>329,699</b>          |                               | <b>301,484,845</b>            |
| 10 December 2012                       | 30,000                  | 928.57                        | 27,857,037                    |
| 11 December 2012                       | 30,000                  | 937.64                        | 28,129,068                    |
| 12 December 2012                       | 29,473                  | 934.16                        | 27,532,471                    |
| 13 December 2012                       | 30,000                  | 928.97                        | 27,868,974                    |
| 14 December 2012                       | 30,000                  | 929.56                        | 27,886,791                    |
| <b>Accumulated under the programme</b> | <b>479,172</b>          |                               | <b>440,759,186</b>            |

With the transactions stated above, Novo Nordisk owns a total of 17,351,991 treasury shares, corresponding to 3.1% of the share capital. The total amount of shares in the company is

560,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 14 December 2012, Novo Nordisk has

**Novo Nordisk A/S**  
Investor Relations

Novo Allé  
2880  
Bagsværd  
Denmark

Telephone:  
+45 4444 8888

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

Telefax:  
+45 4444 2314

CVR no:  
24 25 67 90

Company announcement No 82 / 2012

---

repurchased a total of 12,992,632 B shares equal to a transaction value of DKK 10,940,758,498.

*Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

### **Further information**

#### *Media:*

|                      |                 |                                                                |
|----------------------|-----------------|----------------------------------------------------------------|
| Anne Margrethe Hauge | +45 4442 3450   | <a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a> |
| Ken Inchausti (US)   | +1 609 514 8316 | <a href="mailto:kiou@novonordisk.com">kiou@novonordisk.com</a> |

#### *Investors:*

|                         |                 |                                                                |
|-------------------------|-----------------|----------------------------------------------------------------|
| Kasper Roseeuw Poulsen  | +45 4442 4303   | <a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a> |
| Frank Daniel Mersebach  | +45 4442 0604   | <a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a> |
| Lars Borup Jacobsen     | +45 3075 3479   | <a href="mailto:lbj@novonordisk.com">lbj@novonordisk.com</a>   |
| Jannick Lindegaard (US) | +1 609 786 4575 | <a href="mailto:jlis@novonordisk.com">jlis@novonordisk.com</a> |

**Novo Nordisk A/S**  
Investor Relations

Novo Allé  
2880  
Bagsværd  
Denmark

Telephone:  
+45 4444 8888  
  
Telefax:

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)  
  
CVR no:

Edgar Filing: NOVO NORDISK A S - Form 6-K

+45 4444 2314 24 25 67 90

Company announcement No 82 / 2012

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: December 17, 2012

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer